XML 20 R9.htm IDEA: XBRL DOCUMENT v3.23.3
INVENTORY
 6 Months Ended
Sep. 30, 2023
Inventory Disclosure [Abstract]  
Inventory Disclosure [Text Block]

NOTE 3 – INVENTORY

 

   

(in thousands)

  
   

As of

September 30, 2023

($)

    

As of

March 31, 2023

($)

  

Raw materials

     2,127       2,100  

Work-in-Progress

     11       18  

Finished goods

     498       533  

Total

     2,636       2,651  

 

During the six months ended September 30, 2023, and 2022, the Company wrote off approximately $3 thousand and $40 thousand of inventory due to abnormal loss due to idle facility expense, freight, handling costs, scrap, and wasted material (spoilage). This charge was recorded in Selling, General, and Administrative Expenses.

 

We capitalize inventory costs related to our investigational drug, provided that management determines there is a potential alternative use for the inventory in future research and development projects or other purposes. As of September 30, 2023, and March 31, 2023, our consolidated balance sheet reported approximately $397 thousand and $407 thousand clinical trial-related inventory, respectively.